Top

Strahlentherapie und Onkologie

Published in:

01-12-2017 | Original Article

Low-dose total skin electron beam therapy for cutaneous lymphoma

Minimal risk of acute toxicities

Authors: Kai Kroeger, Khaled Elsayad, MD, Christos Moustakis, Uwe Haverkamp, Hans Theodor Eich

Published in: Strahlentherapie und Onkologie | Issue 12/2017

Abstract

Background

Low-dose total skin electron beam therapy (TSEBT) is attracting increased interest for the effective palliative treatment of primary cutaneous T‑cell lymphoma (pCTCL). In this study, we compared toxicity profiles following various radiation doses.

Patients and methods

We reviewed the records of 60 patients who underwent TSEBT for pCTCL between 2000 and 2016 at the University Hospital of Munster. The treatment characteristics of the radiotherapy (RT) regimens and adverse events (AEs) were then analyzed and compared.

Results

In total, 67 courses of TSEBT were administered to 60 patients. Of these patients, 34 (51%) received a standard dose with a median surface dose of 30 Gy and 33 patients (49%) received a low dose with the median surface dose of 12 Gy (7 salvage low-dose TSEBT courses were administered to 5 patients). After a median follow-up of 15 months, the overall AE rate was 100%, including 38 patients (57%) with grade 2 and 7 (10%) with grade 3 AEs. Patients treated with low-dose TSEBT had significantly fewer grade 2 AEs than those with conventional dose regimens (33 vs. 79%, P < 0.001). A lower grade 3 AE rate was also observed in patients who had received the low-dose regimen compared to those with the conventional dose regimens (6 vs. 15%, P = 0.78). Multiple/salvage low-dose TSEBT courses were not associated with an increased risk of acute AEs.

Conclusion

Low-dose TSEBT regimens are associated with significantly fewer grade 2 acute toxicities compared with conventional doses of TSEBT. Repeated/Salvage low-dose TSEBT, however, appears to be tolerable and can even be applied safely in patients with cutaneous relapses.

Talpur R, Singh L, Daulat S et al (2012) Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res 18(18):5051–5060. doi:10.1158/1078-0432.ccr-12-0604 CrossRefPubMed

Agar NS, Wedgeworth E, Crichton S et al (2010) Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28(31):4730–4739. doi:10.1200/jco.2009.27.7665 CrossRefPubMed

Elsayad K, Susek KH, Eich HT (2017) Total skin electron beam therapy as part of multimodal treatment strategies for primary cutaneous T‑cell lymphoma. Oncol Res Treat 40(5):244–252. doi:10.1159/000475634 CrossRefPubMed

Stadler R, Assaf C, Klemke C‑D et al (2008) Short German guidelines: cutaneous lymphomas. J Dtsch Dermatol Ges 6(Suppl 1):31. doi:10.1111/j.1610-0387.2008.06710.x

Willemze R, Hodak E, Zinzani PL et al (2013) Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi149–vi154. doi:10.1093/annonc/mdt242 CrossRefPubMed

Trautinger F, Eder J, Assaf C et al (2017) European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome – update 2017. Eur J Cancer 77(0):57–74. doi:10.1016/j.ejca.2017.02.027 CrossRefPubMed

Hoppe RT (2017) Remarkable advances in the management of mycosis fungoides and the Sezary syndrome. Oncol Res Treat 40(5):242–243. doi:10.1159/000475528 CrossRefPubMed

Harrison C, Young J, Navi D et al (2011) Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 81(4):e651–e657. doi:10.1016/j.ijrobp.2011.01.023 CrossRefPubMed

Morris SL, McGovern M, Bayne S et al (2013) Results of a 5-week schedule of modern total skin electron beam radiation therapy. Int J Radiat Oncol Biol Phys 86(5):936–941. doi:10.1016/j.ijrobp.2013.04.042 CrossRefPubMed

10.

Lloyd S, Chen Z, Foss FM et al (2013) Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. J Am Acad Dermatol 69(4):537–543. doi:10.1016/j.jaad.2013.04.063 CrossRefPubMed

11.

Haas RLM, Poortmans P, de Jong D et al (2003) High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 21(13):2474–2480. doi:10.1200/jco.2003.09.542 CrossRefPubMed

12.

Lowry L, Smith P, Qian W et al (2011) Reduced dose radiotherapy for local control in Non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 100(1):86–92. doi:10.1016/j.radonc.2011.05.013 CrossRefPubMed

13.

Herfarth K, Koenig L (2014) Radiotherapy (4 Gy vs. 24 Gy) of patients with indolent Non-Hodgkin-Lymphoma. Strahlenther Onkol 190(11):1084–1085. doi:10.1007/s00066-014-0728-8 CrossRefPubMed

14.

Koenig L, Stade R, Rieber J et al (2016) Radiotherapy of indolent orbital lymphomas two radiation concepts. Strahlenther Onkol 192(6):414–421. doi:10.1007/s00066-016-0962-3 CrossRef

15.

Habibeh O, Elsayad K, Kriz J et al (2017) Lymphoproliferative Erkrankung nach Transplantation erfolgreich durch konsolidierende Bestrahlung behandelt (Post-transplant lymphoproliferative disorder in the pelvis successfully treated with consolidative radiotherapy). Strahlenther Onkol 193(1):80–85. doi:10.1007/s00066-016-1006-8 CrossRefPubMed

16.

Elsayad K, Kriz J, Moustakis C et al (2016) Die Renaissance der Ganzhautelektronenbestrahlung zur Behandlung primär kutaner T‑Zell-Lymphome: NiedrBehandlung primär kutaner T‑Zell-Lymphome: Niedrigig vs. konventionell dosierte Radiotherapie (Abstracts DEGRO 2016). Strahlenther Onkol 192(Suppl 1):142. doi:10.1007/s00066-016-0974-z

17.

Hoppe RT, Harrison C, Tavallaee M et al (2015) Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol 72(2):286–292. doi:10.1016/j.jaad.2014.10.014 CrossRefPubMed

18.

Kamstrup MR, Gniadecki R, Iversen L et al (2015) Low-dose (10-Gy) total skin electron beam therapy for cutaneous T‑cell lymphoma: an open clinical study and pooled data analysis. Int J Radiat Oncol Biol Phys 92(1):138–143. doi:10.1016/j.ijrobp.2015.01.047 CrossRefPubMed

19.

Elsayad K, Oertel M, Haverkamp U et al (2017) The effectiveness of radiotherapy for leukemia cutis. J Cancer Res Clin Oncol 143(5):851–859. doi:10.1007/s00432-016-2338-6 CrossRefPubMed

20.

Dabaja B (2017) Renaissance of low-dose radiotherapy concepts for cutaneous lymphomas. Oncol Res Treat 40(5):255–260. doi:10.1159/000470845 CrossRefPubMed

21.

Morris SL, Scarisbrick J, Frew JJ et al (2017) The results of low dose total skin electron beam radiotherapy (TSEB), in patients with mycosis fungoides from the UK cutaneous lymphoma group. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2017.05.052

22.

Elsayad K, Kriz J, Moustakis C et al (2015) Total skin electron beam for primary cutaneous T‑cell lymphoma. Int J Radiat Oncol Biol Phys 93(5):1077–1086. doi:10.1016/j.ijrobp.2015.08.041 CrossRefPubMed

23.

Lindahl LM, Kamstrup MR, Petersen PM et al (2011) Total skin electron beam therapy for cutaneous T‑cell lymphoma: a nationwide cohort study from Denmark. Acta Oncol (Madr) 50(8):1199–1205. doi:10.3109/0284186x.2011.585999 CrossRef

24.

Licata AG (1995) Malignant melanoma and other second cutaneous malignancies in cutaneous T‑cell lymphoma. The influence of additional therapy after total skin electron beam radiation. Arch Dermatol 131(4):432–435. doi:10.1001/archderm.131.4.432 CrossRefPubMed

25.

Wilson LD, Quiros PA, Kolenik S et al (1994) Additional courses of total skin electron beam therapy [TSEBT] in the retreatment of patients with cutaneous t‑cell lymphoma [CTCL]. Int J Radiat Oncol Biol Phys 30:269. doi:10.1016/0360-3016(94)90825-7 CrossRef

26.

Becker M, Hoppe RT, Knox SJ (1995) Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys 32(5):1445–1449. doi:10.1016/0360-3016(94)00590-h CrossRefPubMed

27.

Navi D, Riaz N, Levin YS et al (2011) The stanford university experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 147(5):561. doi:10.1001/archdermatol.2011.98 CrossRefPubMed

28.

Hoppe RT, Harrison C, Tavallaee M et al (2015) Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides. Results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol 72(2):286–292. doi:10.1016/j.jaad.2014.10.014 CrossRefPubMed

29.

Trautinger F, Eder J, Assaf C et al (2017) European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – update 2017. Eur J Cancer 77:57–74. doi:10.1016/j.ejca.2017.02.027 CrossRefPubMed

30.

Kim YH, Duvic M, Obitz E et al (2007) Clinical efficacy of zanolimumab (HuMax-CD4). Two phase 2 studies in refractory cutaneous T‑cell lymphoma. Blood 109(11):4655–4662. doi:10.1182/blood-2006-12-062877 CrossRefPubMed

31.

de Masson A, Guitera P, Brice P et al (2014) Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T‑cell lymphomas. Br J Dermatol 170(3):720–724. doi:10.1111/bjd.12690 CrossRefPubMed

32.

Ogura M, Ishida T, Hatake K et al (2014) Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T‑cell lymphoma and cutaneous T‑cell lymphoma. J Clin Oncol 32(11):1157–1163. doi:10.1200/jco.2013.52.0924 CrossRefPubMed

33.

Duvic M, Tetzlaff MT, Gangar P et al (2015) Results of a phase II trial of brentuximab vedotin for CD30 + cutaneous T‑cell lymphoma and lymphomatoid papulosis. J Clin Oncol 33(32):3759–3765. doi:10.1200/jco.2014.60.3787 CrossRefPubMedPubMedCentral

34.

Duvic M, Pinter-Brown LC, Foss FM et al (2015) Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T‑cell lymphoma. Blood 125(12):1883–1889. doi:10.1182/blood-2014-09-600924 CrossRefPubMedPubMedCentral

Title: Low-dose total skin electron beam therapy for cutaneous lymphoma
Minimal risk of acute toxicities
Authors: Kai Kroeger
Khaled Elsayad, MD
Christos Moustakis
Uwe Haverkamp
Hans Theodor Eich
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 12/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-017-1188-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Low-dose total skin electron beam therapy for cutaneous lymphoma

Minimal risk of acute toxicities

Abstract

Background

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2017

Patterns of failure of diffuse large B‑cell lymphoma patients after involved-site radiotherapy

BioXmark for high-precision radiotherapy in an orthotopic pancreatic tumor mouse model

Radiochemotherapie verbessert „failure-free survival“ beim Endometriumkarzinom im Stadium III

Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer

Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy

Time for crowd knowledge-based approach in SBRT planning